# CDK4 vs CDK6: dependency and drugs side by side

> CDK4 vs CDK6 in DepMap and drug data: 786 of 1178 cell lines depend on CDK4, 595 on CDK6, and four approved drugs are annotated to both genes.

Data as of 2026-11-06 · Published 2026-11-06 · Updated 2026-11-06 · https://bioq.bio/blog/en/compare-cdk4-vs-cdk6

![BioQ results page for the query CDK4, showing the DepMap dependency summary by lineage and the list of known drugs with their clinical stage.](https://bioq.bio/blog/img/compare-cdk4-vs-cdk6/en/hero.webp)

In DepMap, CDK4 knockout reduces viability in 786 of 1178 cell lines (66.7%) and the gene is flagged common essential. CDK6 does so in 595 of the same 1178 lines (50.5%) and is not flagged. Both genes share the same four drug names at the top of their lists, all at the approval stage. Data are as of 2026-11-06.

## What we asked: CDK4 vs CDK6 side by side

CDK4 and CDK6 are paralogs that both bind D-type cyclins, and the approved inhibitors are usually described as acting on both. Two questions follow for anyone choosing a model system or reading a screen.

- How does the CRISPR dependency of each gene differ across the same set of cell lines?
- Which drugs does the annotation attach to each gene, and how do their potency values compare?

We ran the same two blocks for each gene: a DepMap dependency summary by lineage (top 5 lineages) and a drug list (6 shown). Putting both genes through identical blocks keeps the comparison honest, because the cell line set, the release and the drug sources are the same on both sides.

## What BioQ returned

The dependency data come from the depmap_24q4 release, using the Chronos gene effect. A more negative value means the knockout reduced viability more. A line counts as dependent when its effect falls at or below a fixed cutoff that the engine defines as a named constant. The cutoff is a convention, not a measured property of the data.

CDK4 across lineages:

| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| Bone | 46 | 36 | 78.3 | -1.216 |
| Prostate | 10 | 8 | 80 | -1.168 |
| Eye | 15 | 14 | 93.3 | -1.161 |
| Breast | 53 | 43 | 81.1 | -1.129 |
| Skin | 74 | 59 | 79.7 | -0.875 |

CDK6 across lineages:

| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| Myeloid | 42 | 33 | 78.6 | -1.057 |
| Lymphoid | 93 | 68 | 73.1 | -0.953 |
| Peripheral Nervous System | 44 | 32 | 72.7 | -0.85 |
| Head and Neck | 77 | 60 | 77.9 | -0.848 |
| Biliary Tract | 35 | 25 | 71.4 | -0.778 |

The drug layer combines Open Targets, ChEMBL, the Drug Repurposing Hub and ClinicalTrials.gov. For CDK4 it lists 27 drugs, of which 6 are shown:

| Drug | Max clinical stage | Mechanism | Best exact pChEMBL | Type | Trials by name |
|---|---|---|---|---|---|
| Abemaciclib | APPROVAL | Cyclin-dependent kinase 4 inhibitor | 9.59 | IC50 | 194 |
| Palbociclib | APPROVAL | Cyclin-dependent kinase 4/cyclin D1 inhibitor | 9.59 | KI | 244 |
| Trilaciclib | APPROVAL | Cyclin-dependent kinase 4 inhibitor | 9.1 | IC50 | 28 |
| Ribociclib | APPROVAL | Cyclin-dependent kinase 4 inhibitor | 8.7 | IC50 | 126 |
| Ribociclib Succinate | APPROVAL | Cyclin-dependent kinase 4 inhibitor | — | — | 1 |
| Trilaciclib Dihydrochloride | APPROVAL | Cyclin-dependent kinase 4 inhibitor | — | — | 0 |

For CDK6 the list holds 17 drugs. The shown rows carry the same six names in a slightly different order, with these exact pChEMBL values: palbociclib 9.7, abemaciclib 9.37, trilaciclib 8.4 and ribociclib 8.22. The two salt forms, ribociclib succinate and trilaciclib dihydrochloride, have no exact pChEMBL value on either gene.

![BioQ results for CDK4 with the drug table listing abemaciclib, palbociclib, trilaciclib and ribociclib with their clinical stage and pChEMBL values](https://bioq.bio/blog/img/compare-cdk4-vs-cdk6/en/second.webp)
*Drug layer for CDK4 in BioQ, with potency and trial counts per drug.*

## What it means and how to read it

**Where the genes are alike.** Both genes show a negative mean gene effect across all 1178 lines (-0.765 for CDK4, -0.588 for CDK6), and both have a clear majority or near-majority of dependent lines. In both cases the strongest lineages reach a mean gene effect below -0.9 or better. Both drug lists are led by the same four molecules at the approval stage.

**Where they differ.** CDK4 is the broader dependency: 66.7% of lines against 50.5%, and only CDK4 carries the common essential flag. The top lineages do not overlap in the lists returned. For CDK4 they are Bone (mean -1.216), Prostate (-1.168), Eye (-1.161), Breast (-1.129) and Skin (-0.875). For CDK6 they are Myeloid (-1.057), Lymphoid (-0.953), Peripheral Nervous System (-0.85), Head and Neck (-0.848) and Biliary Tract (-0.778). The CDK6 pattern leans toward blood and neural lineages, while the CDK4 pattern leans toward solid tissues. Eye reaches 93.3% dependent (14 of 15 lines), the highest percentage in either table, but the lineage is small.

**Drug potency.** For abemaciclib (9.59 against 9.37), trilaciclib (9.1 against 8.4) and ribociclib (8.7 against 8.22) the exact value is higher on CDK4. Palbociclib is the reverse, with 9.59 on CDK4 and 9.7 on CDK6. The trial counts by drug name are identical on both sides (244 for palbociclib, 194 for abemaciclib, 126 for ribociclib, 28 for trilaciclib), because they count trials mentioning the drug, not the gene.

**Why one query helps.** These four blocks drew on 2 distinct resources and took 0.61 seconds of engine time over 4 queries. Assembling the same view by hand means downloading a DepMap release, grouping by lineage, and then matching drug names across the potency and trial sources. The result here is the same comparison, with each answer naming its source.

## How to reproduce it in BioQ

1. Open BioQ and paste the query below into the search box.

```text
CDK4
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3DCDK4)

2. Read the dependency block for CDK4 and note the cell line counts, the percentage dependent and the common essential flag.
3. Open the drug block for CDK4 and note the maximum clinical stage and the exact pChEMBL value of each drug.
4. Repeat the query with CDK6 in place of CDK4, and compare the two sets of blocks row by row.
5. Check the release label on the dependency block (depmap_24q4) before you cite any value, so that your numbers match the release you used.

## Limits: what the data do not show

- **Selectivity is not established here.** The exact pChEMBL column gives one value per drug and gene, and the assay type differs between rows (KI for palbociclib, IC50 for the others). Values from different assays are not a matched comparison, so they cannot settle CDK4 CDK6 selectivity.
- **Only the top 5 lineages are shown.** Lineages outside the list may also depend on either gene, and small lineages such as Prostate (10 lines) give unstable percentages.
- **The dependent cutoff is a convention.** Changing it would change the counts and percentages.
- **Paralog compensation is not measured here.** The data do not show whether CDK6 buffers loss of CDK4 or the reverse in a given line, nor how pathway status or expression shapes the pattern.
- **Cell lines are not patients.** Dependency in a culture dish says nothing about response in a person, and nothing on this page is guidance for treatment or dosing.
- **Trial counts are by drug name.** They include trials unrelated to CDK4 or CDK6 as a target, and they say nothing about outcomes.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (4 queries, 0.6 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/depmap`, `/drugs`

Run the same query yourself: [CDK4](https://bioq.bio/login?next=%2Fapp%23q%3DCDK4)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`CDK4`](https://bioq.bio/login?next=%2Fapp%23q%3DCDK4)

## Frequently asked questions

### Is CDK4 or CDK6 the more common dependency in DepMap?

CDK4. In depmap_24q4 it is a dependency in 786 of 1178 cell lines (66.7%) and is flagged common essential, while CDK6 is a dependency in 595 of 1178 (50.5%) and is not flagged.

### Which lineages depend most on CDK4 and which on CDK6?

Among the top 5 lineages returned, CDK4 is led by Bone (mean gene effect -1.216) and Prostate (-1.168). CDK6 is led by Myeloid (-1.057) and Lymphoid (-0.953). The two lists do not share a lineage.

### Do the same drugs target CDK4 and CDK6?

In the annotation, yes: abemaciclib, palbociclib, trilaciclib and ribociclib appear for both genes at the approval stage. CDK4 has 27 drugs listed and CDK6 has 17.

### Can pChEMBL values tell me which inhibitor is selective for CDK4 over CDK6?

Not reliably. Trilaciclib has 9.1 on CDK4 and 8.4 on CDK6, but the values are single exact entries with different assay types (KI or IC50), not matched pairs from one experiment.

## Sources

- Dataset: [DepMap CRISPR Chronos gene effect (24Q4)](https://depmap.org/portal/)
- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
